

MIEBO® Prior Authorization Checklist

Use this checklist as a guide when completing prior authorizations (PAs) to help ensure necessary information is documented. Note: Incomplete or missing information may result in a PA denial.

Miebo
(perfluorohexyloctane
ophthalmic solution)

REQUESTED MEDICATION FOR TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

MIEBO® (perfluorohexyloctane ophthalmic solution) 30-day supply (3 mL in a 5-mL bottle)

CONTINUING MIEBO PATIENT:

PROVIDE THE REQUIRED DOCUMENTATION DETAILED BELOW, INCLUDING CHART NOTES

- Patient was **previously treated with MIEBO and achieved or maintained improvement in their signs and symptoms of DED from baseline** (eg, ocular irritation, redness, visual function, ocular surface findings, tear production). Including before and after diagnostics is helpful.
- MIEBO has **no generic or FDA-approved therapeutic equivalent**.
- **Continuing MIEBO is essential to preserve the patient's therapeutic progress** and ensure continuity of care.

NEW MIEBO PATIENT:

1. ■ PROVIDE THE REQUIRED DOCUMENTATION DETAILED BELOW, INCLUDING CHART NOTES

☐ Clinical diagnosis of dry eye disease (DED), including the following information¹:

- Date of diagnosis
- Valid ICD-10 diagnostic code and ICD-10 symptom code with full 7 characters and description (see other side for list of codes), and include secondary code when applicable
- Test results, including clinical score and chart notes¹
- ☐ Slit lamp exam
- ☐ **ONE additional diagnostic test result** from the following list is recommended:
 - Tear breakup time (TBUT) <10 seconds
 - Ocular Surface Disease Index 6 (OSDI-6): ≥4
 - Ocular surface staining (>5 corneal or >9 conjunctival punctate spots)
 - Tear osmolality
 - Aqueous tear production (Schirmer test)
 - Matrix metalloproteinase-9 (MMP-9) test
 - MGD evaluation (lid margin staining >2 mm length and >25% width)

☐ Tried and failed prior treatment history for DED

Patient has previously attempted other treatments for DED, but those trials have failed to provide a necessary response due either to inadequate efficacy or lack of tolerability.

- **Documentation of all prior therapies** (eg, warm compresses, artificial tears, lubricants, gels, ointments, punctal plugs, cyclosporine, or other prescription medication)
- **Include dates, duration, and outcomes** (eg, patient did not tolerate treatment due to side effects or treatment failed to produce adequate response)

☐ Patient-reported dry eye symptoms, such as¹:

- | | | | |
|---------------|--------------------------|-----------------------------------|--|
| • Irritation | • Foreign body sensation | • Contact lens intolerance | • Eye fatigue |
| • Watery Eyes | • Mild itching | • Redness | • Symptoms that fluctuate and/or worsen later in the day |
| • Burning | • Photophobia | • Mucus discharge | • Other: |
| • Stinging | • Blurry vision | • Increased frequency of blinking | |
| • Dryness | | | |

☐ Functional impact of DED

- | | | | |
|-----------|--------------------|--------------------|------------------------|
| • Reading | • Using a computer | • Driving at night | • Productivity at work |
|-----------|--------------------|--------------------|------------------------|

2. ■ ATTACH A COPY OF THE LETTER OF MEDICAL NECESSITY

3. ■ ENSURE PRESCRIBER SIGNATURE IS INCLUDED

Indication

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

Important Safety Information

- MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane

Please see additional Important Safety Information on reverse side and click [here](#) for full Prescribing Information.

MIEBO® ICD-10 Coding

These diagnosis code examples are provided for general informational purposes only and are not intended to be directive, a guarantee of coverage, or a substitute for an independent clinical decision.

Miebo
(perfluorohexyloctane
ophthalmic solution)

PRIMARY EXAMPLE ICD-10 CODES FOR DRY EYE DIAGNOSIS²

DESCRIPTION	RIGHT	LEFT	BILATERAL	UNSPECIFIED
Dry eye syndrome of lacrimal gland	H04.121	H04.122	H04.123	H04.129
Unspecified epiphora	H04.201	H04.202	H04.203	H04.209
Unspecified superficial keratitis	H16.101	H16.102	H16.103	H16.109
Punctate keratitis	H16.141	H16.142	H16.143	H16.149
Unspecified keratoconjunctivitis	H16.201	H16.202	H16.203	H16.209
Keratoconjunctivitis sicca, not specified as Sjögren's syndrome	H16.221	H16.222	H16.223	H16.229
Other keratoconjunctivitis	H16.291	H16.292	H16.293	H16.299

Sicca syndrome (Sjögren), unspecified—M35.00

Sicca syndrome (Sjögren) with keratoconjunctivitis—M35.01

PRIMARY EXAMPLE ICD-10 CODES FOR DRY EYE SYMPTOMS²

DESCRIPTION	RIGHT	LEFT	BILATERAL	UNSPECIFIED
Visual discomfort	H53.141	H53.142	H53.143	H53.149

Other visual disturbances—H53.8

SECONDARY EXAMPLE ICD-10 CODES FOR DRY EYE DIAGNOSIS²

DESCRIPTION	RIGHT	LEFT
Meibomian gland dysfunction of eyelid, upper eyelid	H02.881	H02.884
Meibomian gland dysfunction of eyelid, lower eyelid	H02.882	H02.885
Meibomian gland dysfunction of eye, unspecified eyelid	H02.883	H02.886
Meibomian gland dysfunction of eye, upper and lower eyelids	H02.88A	H02.88B

Meibomian gland dysfunction of unspecified eye, unspecified eyelid—H02.889

This information is for reference only. Bausch + Lomb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the eye care professional to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement.

Important Safety Information (cont'd)

- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Please click [here](#) for full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Wolffsohn JS, Benitez-del-Castillo JM, Loya-Garcia D, et al. TFOS DEWS III: diagnostic methodology. *Am J Ophthalmol.* 2025;279:387–450. doi:10.1016/j.ajo.2025.05.033 2. Centers for Disease Control and Prevention. ICD-10-CM tabular list of diseases and injuries. Published April 2022. Accessed June 29, 2026. https://ftp.cdc.gov/pub/health_statistics/nchs/publications/ICD10CM/2022/icd10cm-tabular-2022-April-1.pdf

QUESTIONS?

Your Field Access
Manager is ready to help!



Contact your
Field Access
Manager today.